Skip to content
HelixEVOLabs home
Sign in
HelixEVO LabsBPC-157TB-50030 mgLOT ________For research use only. Not for human or veterinary use.STORE 2–8 °CHelixEVO LabsBPC-157TB-50030 mgLOT ________For research use only.Not for human or veterinary use.STORE 2–8 °C
Research blend

BPC-157 / TB-500 blend

BPC-157 / TB-500

Specification
Total quantity
30 mg
Pack
Sealed glass vial(s); vial count confirmed before release
Form
Lyophilised powder
Stated purity
Reported per lot on the certificate of analysis
Appearance
White to off-white lyophilised powder in a sealed glass vial under an aluminium crimp seal.
Storage
2–8 °C, sealed, protected from light
Shipping
Dispatched from the United Kingdom Monday to Wednesday only, under cold chain in insulated packaging with coolant, so that no consignment is held over a weekend in transit.
SKU
HX-BT-30
AvailabilityOut of stock

Pricing releasing soon. Leave an email to be told once, or request a wholesale quote now.

Request a wholesale quote
For laboratory research use only. Not for human or veterinary consumption.

Analytical data

Latest released lotNo released lot yet

Analytical data appear here as soon as the first lot is released. Every released lot carries a certificate with HPLC purity and MS identity per compound.

Method

Purity by reversed-phase HPLC with UV detection; identity by electrospray mass spectrometry against the calculated monoisotopic or average mass. Endotoxin where stated. The certificate names the laboratory and the method for every result.

How to read a certificate →

Identity

Identity · BPC-157verified 2026-09-21
Synonyms
Bepecin, BPC 157, PL-10, PL-14736, PLD-116, Body protection compound 157, H-GEPPPGKPADDAGLV-OH
CAS
137525-51-0· FDA / NCATS Global Substance Registration System, PubChem, National Center for Biotechnology Information, U.S. Food and Drug Administration
UNII
8ED8NXK95P· FDA / NCATS Global Substance Registration System, U.S. Food and Drug Administration
PubChem CID
9941957
Formula
C62H98N16O22· PubChem, National Center for Biotechnology Information, FDA / NCATS Global Substance Registration System, U.S. Food and Drug Administration
Mol. weight
1419.5 g/mol· PubChem, National Center for Biotechnology Information, U.S. Food and Drug Administration
Class
Synthetic pentadecapeptide; reported to be a partial sequence of a body protection compound (BPC) isolated from human gastric juice
Targets
None identified in retrieved sources
Modifications
None; linear pentadecapeptide with a free N-terminal amine and a free C-terminal carboxyl, no amidation, acylation, cyclisation, disulfide or non-natural residue recorded
Sequence (one-letter) · 15 residues
  1. G
  2. E
  3. P
  4. P
  5. P
  6. G
  7. K
  8. P
  9. A
  10. D
  11. D
  12. A
  13. G
  14. L
  15. V
Identity · TB-500verified 2026-09-22
Synonyms
—
CAS
Not yet verified
UNII
Not yet verified
PubChem CID
Not yet verified
Formula
Not yet verified
Mol. weight
Not yet verified
Class
Not yet verified
Targets
None identified in retrieved sources

Identity fields marked “not yet verified” are withheld until they can be traced to a retrieved primary source. Nothing is shown from memory or from supplier catalogues.

Research overview

The preparation contains two compounds. BPC-157 is a synthetic pentadecapeptide of sequence GEPPPGKPADDAGLV, described by FDA as reported to be a partial sequence of a body protection compound isolated from human gastric juice 12. Its identity records give CAS 137525-51-0, UNII 8ED8NXK95P and PubChem CID 9941957, with molecular formula C62H98N16O22 and a molecular weight of 1419.5 g/mol 34. No record of BPC-157 as an authorised active substance was found in the MHRA products substance index on 21 September 2026 5. TB-500 is a trade name applied to two different molecules: a synthetic N-acetylated heptapeptide corresponding to residues 17 to 23 of thymosin beta-4, registered under UNII QHK6Z47GTG with CAS 885340-08-9 and a molecular weight of 889.0 g/mol, and full-length thymosin beta-4 itself, a 43-residue peptide given the international non-proprietary name timbetasin 678. Laboratories that analysed material sold under the TB-500 name identified the acetylated heptapeptide as the key ingredient 910. Both compounds appear on the World Anti-Doping Agency Prohibited List in force, BPC-157 in section S0 and thymosin beta-4 with its derivatives in section S2.3 11. The linked monographs set out identifiers, the published literature and dated status for each compound separately.

  1. 1.Tu M, Adeyemi O, Rupp T, Albuquerque E, Benedict A, Hankla E, Kasim S. FDA Briefing Document, Pharmacy Compounding Advisory Committee: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration (2026). source
  2. 2.Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, and colleagues. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology (Paris) (1993). doi:10.1016/0928-4257(93)90038-u
  3. 3.BPC-157 substance record, UNII 8ED8NXK95P (FDA Global Substance Registration System). FDA / NCATS Global Substance Registration System (2026). source
  4. 4.BPC-157, CID 9941957: molecular formula, molecular weight, IUPAC name, SMILES and synonyms. PubChem, National Center for Biotechnology Information (2026). source
  5. 5.MHRA Products substance index, letter B. Medicines and Healthcare products Regulatory Agency (2026). source
  6. 6.FDA Global Substance Registration System: TB-500 (UNII QHK6Z47GTG). FDA / NCATS GSRS (2026). source
  7. 7.Mathew B, Mattingly A, Rupp T, Albuquerque E, Benedict A, Kneeream E, Kasim S (FDA CDER). FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting July 23-24, 2026: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration (2026). source
  8. 8.FDA Global Substance Registration System: TIMBETASIN (UNII 2D5MRE3SSY). FDA / NCATS GSRS (2026). source
  9. 9.Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis (2012). doi:10.1002/dta.1402
  10. 10.Ho ENM, Kwok WH, Lau MY, Wong ASY, Wan TSM, Lam KKH, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A (2012). doi:10.1016/j.chroma.2012.09.043
  11. 11.The Prohibited List (List of Prohibited Substances and Methods in force). World Anti-Doping Agency (2026). source
BPC-157 monographTB-500 monograph

Regulatory status

Regulatory status · BPC-157Investigational or unlicensed compound

No medicine containing this compound is authorised in any jurisdiction checked. It has no established safety profile in humans outside registered clinical research. It is supplied for laboratory research only.

The rows below record the absence of authorisation and any compounding, evaluation or anti-doping status found on the date checked.

United Kingdom
No record of BPC-157 or bepecin as an authorised active substance was found in the MHRA products substance index on 2026-09-21.Checked 2026-09-21 · Medicines and Healthcare products Regulatory Agency
European Union
No record found in the European Commission Union Register of medicinal products for human use on 2026-09-21.Checked 2026-09-21 · European Commission, DG SANTE
United States
Not FDA-approved in any product; FDA proposed in May 2026 not to add BPC-157 (free base) or BPC-157 acetate to the 503A bulk drug substances list, and the substance sits on FDA's list of bulk drug substances nominated but withdrawn, previously in category 2.Checked 2026-09-21 · U.S. Food and Drug Administration
WADA Prohibited List
Prohibited at all times as a named example in section S0, Non-Approved Substances, of the Prohibited List in force; all substances in S0 are Specified Substances.Checked 2026-09-21 · World Anti-Doping Agency
Regulatory status · TB-500Investigational or unlicensed compound

No medicine containing this compound is authorised in any jurisdiction checked. It has no established safety profile in humans outside registered clinical research. It is supplied for laboratory research only.

The rows below record the absence of authorisation and any compounding, evaluation or anti-doping status found on the date checked.

United Kingdom
No UK marketing authorisation: the MHRA products index returns no document for 'thymosin' or 'timbetasin' (searched 2026-09-22), and no UK orphan designation or MHRA notice specific to thymosin β4 or TB-500 was found.Checked 2026-09-22 · Medicines and Healthcare products Regulatory Agency
European Union
No centrally authorised medicine and no orphan designation: the Union Register of medicinal products for human use (1,544 entries) and the Community Register of orphan medicinal products (2,194 designations), both last updated 21/09/2026, contain no entry for thymosin, timbetasin, RGN-259 or RGN-137.Checked 2026-09-22 · European Commission, DG Health and Food Safety
United States
Not approved (Drugs@FDA has no record for thymosin, timbetasin or TB-500 on 2026-09-22); FDA's May 2026 evaluation concludes the criteria weigh against placing TB-500 (free base) and TB-500 acetate on the 503A bulks list, the substance is listed on FDA's page of nominated substances that may present significant safety risks, and FDA has told a manufacturer that marketed Thymosin Beta-4 is an unapproved new drug and an unlicensed biological product.Checked 2026-09-22 · U.S. Food and Drug Administration
WADA Prohibited List
Prohibited at all times (in- and out-of-competition) under S2.3 'Growth factors and growth factor modulators' as 'Thymosin-β4 and its derivatives e.g. TB-500'; S2 substances are non-Specified.Checked 2026-09-22 · World Anti-Doping Agency
Handling and safety

Handle as a research chemical of unknown hazard in a laboratory setting with appropriate protective equipment. Keep sealed at 2–8 °C and protected from light. Safety data sheet: available on request until the SDS is published here.

Shipping

Dispatched in insulated cold-chain packaging with a coolant, Monday to Wednesday, to laboratory and business addresses within the United Kingdom. Destination rules are on the shipping policy.

Questions

Which identity records do the two components correspond to?
BPC-157 is recorded as CAS 137525-51-0, UNII 8ED8NXK95P, PubChem CID 9941957, formula C62H98N16O22, 1419.5 g/mol; a separate substance record exists for the acetate salt [gsrs-bpc157-2026][pubchem-cid-9941957][gsrs-bpc157-acetate-2026]. For TB-500 the molecule is not yet confirmed: the registered substance of that name is the acetylated 17 to 23 heptapeptide, UNII QHK6Z47GTG, while full-length thymosin beta-4 is a separate substance [gsrs-qhk6z47gtg][fda-pcac-tb500-briefing-2026].
How does one certificate of analysis cover two compounds?
Each compound carries its own lines on the same certificate: a chromatographic purity figure with the high-performance liquid chromatography method used, and a mass-spectrometric identity line giving the method, the expected and observed masses and whether identity was confirmed, together with assayed mass and net peptide content. Two components therefore produce two result rows on one certificate, and no combined purity figure is recorded.
Is a compendial specification available for either component?
No. Neither compound has a United States Pharmacopeia, National Formulary or European Pharmacopoeia monograph, so no compendial specification or official reference standard can be quoted and each certificate line rests on the stated method [fda-pcac-briefing-2026][fda-pcac-tb500-briefing-2026].
What storage figures are published for the two compounds?
For BPC-157, FDA's evaluation reproduces supplier data describing lyophilised material as stable at room temperature for about three weeks, with storage desiccated below -18 °C [fda-pcac-briefing-2026]. For the TB-500 heptapeptide, the same kind of supplier data give the powder at -80 °C for two years or -20 °C for one year, sealed, dry, dark and under nitrogen [fda-pcac-tb500-briefing-2026]. Neither figure is a pharmacopoeial determination.
Why are the solubility and solution-stability fields empty?
Because no source on this site's allow-list characterises the two-component mixture. Figures published for each compound on its own are set out in the linked monographs, where they are attributed to the evaluation that reproduced them. Nothing is entered here that could not be traced to a retrieved source for this material.
What does the pack contain?
Lyophilised powder in a sealed glass vial holding 30 mg of peptide in total across the two components, held at 2 to 8 °C and protected from light until dispatch. The mass of each component has not been confirmed, so the specification panel states total quantity only. Vials are sealed at fill and are not opened again before shipping.